|
DAEWOONG PHARMA is a pharmaceutical company established in 2002 through the spin-off of the pharmaceutical division from DaeWoo. The company develops, manufactures, and sells prescription and over-the-counter drugs, including the novel drugs Fexuprazan (Pexulock) and Enavogliflozin (Enblo), as well as the botulinum toxin Navea (Jeuveau). Its product portfolio also includes the liver health product Ulsan, the antihypertensive Olmetec, and the gastrointestinal drug Gasmotin. DAEWOONG PHARMA operates a digital healthcare division offering the AI-based bed monitoring system thynC, the continuous glucose monitor FreeStyle Libre, the wearable ECG device Mobicare, and the ring-type blood pressure monitor CartBee. The company serves domestic and global markets, with Navea distributed internationally through partners such as Evolus. Its subsidiaries include HanAll Biopharma, which focuses on biopharmaceuticals for autoimmune and ophthalmic diseases, and PT Selatox Bio Pharma, which manages production and brand development in Indonesia. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage daewoong.co.kr |
| Sector Healthcare | IR page daewoong.co.kr/ko | |
|
Tags
botulinum toxin, prescription drugs, digital healthcare, biopharmaceuticals, autoimmune diseases, gastroenterology, diabetes, ophthalmology, neurology, wearable devices, Fexuprazan, Pexulock, Enavogliflozin, Enblo, Navea, Jeuveau, Ulsan, Olmetec, Gasmotin, thynC, FreeStyle Libre, Mobicare, CartBee, Whisky, Bersiporocin, DWN12088, Semaglutide microneedle patch, DWP216, DWP220, HanAll Biopharma, HPI Inc., PT Selatox Bio Pharma, Biotox, Eligard, Norimix, Hairgro, Batoquelimab, HL161BKN, Imemroprubart, HL161ANS, HL192, HL036, Tafanacercept, Pangro Liquid 5%, Medisafe, Evolus, Moksha8, Oxapharma, Pharma Consulting Group S.A., Aghrass Healthcare Limited, JSC Pharmasyntez, Zydus Lifescience Global FZE, Immunovant, Harbour BioMed, NurrOn Pharmaceuticals, CSPC Pharmaceutical Group
|
Press page daewoong.co.kr/ko/product/news |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 1.436T |
| Market cap (USD) | $ 1.057B |
| P/E | 7.29 |
| PEG | 0.11 |
| P/BV | 1.35 |
| P/S | 0.88 |
| P/OCF | 8.86 |
| P/FCF | -13.81 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 21.8% |
| ROI | 19.5% |
| ROIC | 19.6% |
| Profit margin | 12.5% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 66.8% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 58.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.571T | 1.423T | 1.375T | 1.28T | 1.153T | 1.055T | 1.113T | 1.031T | 960.307B | 883.92B | 839.686B | 735.889B | 682.508B |
| Net profit | 195.856B | 24.735B | 121.739B | 42.24B | 24.506B | 12.753B | 22.006B | -1.516B | 31.581B | 26.97B | 42.93B | 31.544B | 58.4B |
| Free cash flow | -42.329B | -103.653B | 26.671B | 53.053B | 10.906B | 74.495B | 35.286B | -9.49B | 34.861B | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 173B | 170B | 179B | 206B | 149B | 161B | 183B | 180B | 215B | 219B |
| ↳ YoY growth | +21.7% | -1.9% | +5.3% | +15.0% | -27.6% | +7.9% | +13.9% | -1.8% | +19.6% | +2.2% |
| ↳ 5y CAGR | +14.9% | +14.8% | +0.9% | -1.5% | +1.5% | +0.1% | +0.9% | +8.1% | ||
| Borrowings, current (KRW) | 108B | 95.7B | 207B | 99.3B | 147B | 256B | 234B | 372B | 0.00 | 162B |
| Borrowings, non-current (KRW) | 289B | — | — | — | 91.5B | 92B | 115B | 65B | 324B | 551B |
| Bonds payable (KRW) | 99.9B | 89.9B | 200B | 89.9B | 89.9B | 200B | 89.8B | 89.9B | 194B | 334B |
| Lease liabilities (KRW) | — | — | 0.00 | 3.4B | 6.56B | 8B | 8.2B | 3.9B | 3.28B | 2.05B |
| Cash and deposits (KRW) | 78.3B | 91.1B | 65.3B | 32.1B | 72.3B | 75.9B | 103B | 112B | 103B | 169B |
| Intangible assets (KRW) | 151B | 174B | 150B | 165B | 179B | 225B | 266B | 297B | 347B | 368B |
| Right-of-use assets (KRW) | — | — | 0.00 | 4.49B | 7.53B | 7.9B | 8.18B | 4.16B | 19.2B | 17B |
| Net debt (borrowings + leases - cash) (KRW) | 211B | 4.61B | 142B | 70.6B | 173B | 280B | 254B | 330B | 225B | 545B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 15.4B | 104B | 47.5B | 57.6B | 101B | 40B | 118B | 136B | 51.5B | 149B |
| Purchases of property, plant and equipment (KRW) | -141B | -69.1B | -57B | -22.3B | -26.5B | -29.1B | -65.2B | -109B | -155B | -192B |
| Purchases of intangible assets (KRW) | -21.8B | -27.7B | -72.3M | -27.8B | -33.2B | -45.7B | -48.1B | -46.8B | -73.9B | -49.8B |
| Change in receivables (cash effect) (KRW) | -21.2B | -27.6B | -12B | -21.8B | 53.7B | -27.9B | -24.4B | -3.7B | — | — |
| Change in inventories (cash effect) (KRW) | -23.1B | -23.7B | -11.3B | 5.4B | -9.74B | -11.8B | -50B | -43.3B | — | — |
| Change in payables (cash effect) (KRW) | 18.1B | 39.1B | -4.84B | 11.3B | 9.33B | 4.92B | 45.5B | 32.3B | — | — |
| Dividends paid (cash effect) (KRW) | -7.22B | -6.19B | -6.19B | -6.19B | -6.19B | -6.46B | -8.07B | -7.28B | -7.74B | -8.08B |
| Interest paid (cash effect) (KRW) | -7.72B | -9.57B | -10B | -10.4B | -10.7B | -9.84B | -11.5B | -16.6B | -23.1B | -23.6B |
| Income taxes paid (cash effect) (KRW) | -9.78B | -7B | -7.91B | -22.3B | -2.91B | — | -9.05B | -8.39B | -38.9B | -14.5B |
| Share-based compensation (KRW) | 194M | 29.3M | 633M | 943M | 1.19B | 2B | 1.84B | 1.62B | — | — |
| Operating cash flow before change in receivables (KRW) | 36.5B | 132B | 59.5B | 79.4B | 47.3B | 67.9B | 143B | 140B | — | — |
| Free cash flow (OCF - PPE - intangibles) (KRW) | -148B | 7.18B | -9.56B | 7.49B | 41.3B | -34.8B | 4.91B | -20.2B | -178B | -92.2B |
| Income detail | ||||||||||
| Research and development expense (KRW) | — | — | — | — | — | — | 164B | 172B | 171B | 180B |
| Total comprehensive income (KRW) | 24.6B | 32.5B | -14.1B | 33.4B | 42.5B | -18.7B | 52.4B | 130B | 20.5B | 206B |
| Comprehensive income to owners (KRW) | 25.1B | 29B | -15.1B | 23.8B | 17.4B | -5.35B | 47.2B | 123B | 33.4B | 209B |
| Provision for credit losses (KRW) | 2.02B | 3.3B | 3.44B | 1.44B | 3.6B | 2.13B | 2.25B | 5.84B | — | — |
| Credit cost ratio (credit losses / average receivables) (%) | 1.3% | 1.9% | 2.0% | 0.8% | 2.0% | 1.4% | 1.3% | 3.2% | — | — |
| Reported | Apr 1, 2019 | Apr 1, 2019 | May 15, 2019 | Mar 30, 2020 | Aug 17, 2021 | Mar 20, 2024 | Aug 14, 2025 | Aug 14, 2025 | Aug 14, 2025 | Mar 18, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding DAEWOONG PHARMA
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.03% | 574 | $ 42.777K | Nov 16, 2026 |
| DEXC | 0.02% | 513 | $ 39.522K | Nov 12, 2026 |
| DFSE | 0.01% | 861 | $ 66.333K | Nov 12, 2026 |
| DFEM | 0.01% | 7,430 | $ 572.419K | Nov 12, 2026 |
| DFAE | 0.00% | 3,471 | $ 267.411K | Nov 12, 2026 |
| DFAX | 0.00% | 3,707 | $ 285.593K | Nov 12, 2026 |
| AVEM | 0.00% | 2,954 | $ 220.146K | Nov 16, 2026 |
| AVXC | 0.00% | 131 | $ 9,762.72 | Nov 16, 2026 |